ClinicalTrials.gg
CompletedNCT01674361Updated Aug 2, 2017

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

A Phase 2 interventional study of Bitopertin and Placebo in Obsessive-Compulsive Disorder, sponsored by Hoffmann-La Roche. Completed at 34 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Obsessive-Compulsive Disorder with a site in United States — 59 open to participants now, 77 under way, 2 of them phase 3. Obsessive-Compulsive Disorder · United States.

Enrollment
59th of 246
99 · median 40
Started
2012
with 14 others
Phase 2
46 of 299
6 open now
Registered
102nd of 299
by date

Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, this one is the 59th largest by enrollment of the 246 interventional ones that give a count, is one of 15 that started in 2012, is one of 46 in phase 2, and was the 102nd registered.

Obsessive-Compulsive Disorder

636 studies on the registry are indexed under Obsessive-Compulsive Disorder; 166 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

59 of the 299 studies in Obsessive-Compulsive Disorder with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 119 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 81 (68%) stop at 75 or younger; 28 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Obsessive-Compulsive Disorder with a site in United States, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of bitopertin in combination with SSRI in participants with obsessive-compulsive disorder. Participants will be randomized to receive either bitopertin 30 milligrams (mg) or bitopertin 10 mg or placebo orally daily in addition to their background therapy with an SSRI. Participants will be allocated to one of two strata. Participants in Stratum 1 will start study drug on Day 1. Participants in Stratum 2 will receive placebo from Day 1 (placebo lead-in) and will then start study drug at the Week 2 visit. Participants in both strata will receive the study drug in addition to their background therapy with an SSRI until Week 16.

03

Conditions studied

  • Obsessive-Compulsive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of OCD as per , Fourth Edition, Text Revision (DSM-IV-TR)
  • On a stable dose of SSRI for at least 8 weeks prior to screening an between screening and Day 1
  • An insufficient response to current treatment with an SSRI given at an adequate dose for at least 12 weeks prior to Day 1
  • Females who are not or surgically sterile and who have (or may have) male sexual partners must agree to use two adequate methods of as defined by protocol from the start of screening until 90 days after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Primary OCD symptom of hoarding
  • More than two unsatisfactory trials within the last 2 years with different serotonin reuptake inhibitors (not including the current treatment with an SSRI) given in an adequate dose for at least 12 weeks
  • Failure of more than three augmentation therapies within the last 2 years
  • Undergoing acute behavioral therapy or having acute behavioral therapy that was completed less than 4 weeks prior to Day 1
  • Any primary Axis I disorder other than OCD
  • Current or prior history of bipolar disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autistic spectrum disorders, borderline personality disorder, or Gilles de la Tourette syndrome if symptoms have persisted into adulthood
  • Any eating disorder within the last 6 months
  • History of DSM-IV-TR-defined substance dependence and/or substance abuse in the last 6 months, with the exception of nicotine
  • Previous treatment with bitopertin or another Glycine transporter 1 inhibitor
  • Positive urine drug screening for cannabis, amphetamines (including 3,4-methylenedioxymethamphetamine [MDMA]/ecstasy), cocaine, barbiturate, and/or opiates
  • Prior or current general medical condition that may impair cognition or other neuropsychiatric functioning
  • less than (\<) 18.5 kilogram per square meter (kg/m\^2) or greater than (>) 40 kg/m\^2
  • Pregnant or lactating women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Bitopertin 30 mg

    Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI. Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI.

    Drug: Bitopertin · Drug: Placebo · Drug: SSRI

  • Experimental
    Bitopertin 10 mg

    Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI. Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI.

    Drug: Bitopertin · Drug: Placebo · Drug: SSRI

  • Placebo comparator
    Placebo

    Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.

    Drug: Placebo · Drug: SSRI

Interventions

  • Bitopertin once daily orally.

    Also known as: RO4917838

  • DrugPlacebo

    Placebo matched to bitopertin once daily orally.

  • DrugSSRI

    Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Score on Yale-Brown Obsessive Compulsive Scale (Y-BOCS) After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1), Week 12; Stratum 2: Baseline (Week 2), Week 14

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1), Week 12; Stratum 2: Baseline (Week 2), Week 14

  2. Percentage of Participants with Response as per Pre-defined Criteria Based on the Y-BOCS and CGI

    Response will be defined as having: At least a 35 percent (%) reduction on the total Y-BOCS score from baseline. A much or very much improved on the Clinical Global Impression of Change (CGI-C) rating from baseline. A combination of at least 35% reduction on the total Y-BOCS score from baseline and much or very much improved on the CGI-C from baseline. Achieved remission, as shown by a total Y-BOCS score less than or equal to (≤)10.

    Time frame: Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14

  3. Change From Baseline in Global Social Functioning Using Sheehan Disability Scale (SDS) Total Score After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1), Week 12; Stratum 2: Baseline (Week 2), Week 14

  4. Change From Baseline in Global Social Functioning Using SDS Domain Scores After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14

  5. Change From Baseline in Obsessive Compulsive Inventory-Revised (OCI-R) Score After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14

  6. Change From Baseline in Columbia Suicide Severity Rating Scale After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14

  7. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14

  8. Change From Baseline in SF-36 - Physical Component Summary After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14

  9. Change From Baseline in SF-36 - Domain Scores After 12 Weeks of Treatment

    Time frame: Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14

  10. Area Under The Concentration-Time Curve of Bitopertin

    Time frame: Pre-dose (0 hour) on Day 56 (Week 8), Day 84 (Week 12), Day 98 (Week 14), Day 112 (Week 16); 3 and 6 hours post-dose on Day 112 (Week 16)

07

Study locations

34 sites
  • Excell Research
    Oceanside, California 92056, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Yale University School of Medicine; Neuroscience Research Training Program
    New Haven, Connecticut 06519, United States
  • Compass Research North, LLC
    Leesburg, Florida 34748, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 3273, United States
  • University of South Florida
    Saint Petersburg, Florida 33701, United States
  • University of South Florida
    Tampa, Florida 33613-4706, United States
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Uni of Chicago; Centre For Advanced Medicine
    Chicago, Illinois 60637, United States
  • Louisiana Research Associates
    New Orleans, Louisiana 70114, United States
  • Massachusetts General Hospital - East
    Boston, Massachusetts 02114, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Ambulatory Research Center (ARC), Department of Psychiatry
    Minneapolis, Minnesota 55454, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • St Louis Clinical Trials
    Saint Louis, Missouri 63141, United States
  • Mount Sinai School of Medicine; Department of Psychiatry
    New York, New York 10029, United States
  • Medical Research Network - New York
    New York, New York 10128, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • North Star Research
    Middleburg Heights, Ohio 44130, United States
  • Ips Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Keystone Clinical Studies, LLC
    Norristown, Pennsylvania 19403, United States
  • Butler Hospital - Department of Psychiatry and Human Behavior
    Providence, Rhode Island 02906, United States
  • Clinical Neuroscience Solutions,Inc
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials, LP
    Austin, Texas 78731, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington 98033, United States
  • Dean Foundation
    Middleton, Wisconsin 53562, United States
  • Chokka Center for Integrative Health
    Edmonton, Alberta T6L 6W6, Canada
  • Okanagan Clinical Trials
    Kelowna, British Columbia V1Y 2H4, Canada
  • True North Clinical Research-Halifax
    Halifax, Nova Scotia B3S 1M7, Canada
  • True North Clinical Research Kentville
    Kentville, Nova Scotia B4N 4K9, Canada
  • McMaster University - MacAnxiety Research Centre
    Hamilton, Ontario L8S 1B7, Canada
  • Sunny Johnson Medical Research Associates Inc.; Medical Research Associates
    Mississauga, Ontario L5M 4N4, Canada
  • START Clinic for Mood & Anxiety Disorders
    Toronto, Ontario M4W 2N4, Canada
08

References and documents

Publications

  • Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimaraes D, Barouh JL, Jesus-Nunes AP, Beanes G, Souza LS, Leal GC, Sanacora G, Miguel EC, Sampaio AS, Quarantini LC. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harv Rev Psychiatry. 2022 Mar-Apr 01;30(2):135-145. doi: 10.1097/HRP.0000000000000330. PubMed 35267254 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2012 to primary completion in Apr 2015, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2012
First posted
Aug 28, 2012
StartActual
Dec 31, 2012
Primary completionActual
Apr 30, 2015
CompletionActual
Apr 30, 2015
Results delay requested
Sep 10, 2013
Last update
Aug 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01674361
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 28, 2012
Start date
Dec 31, 2012
Primary completion
Apr 30, 2015
Completion
Apr 30, 2015
Last update
Aug 2, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion